Liquidia (NASDAQ:LQDA) Stock Gets Price Target Trim from Needham & Company LLC

Liquidia (NASDAQ:LQDA) had its price objective cut by investment analysts at Needham & Company LLC from $72.00 to $58.00 in a research note issued on Wednesday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Needham & Company LLC’s price objective suggests a potential upside of 116.34% from the company’s previous close.

Several other equities analysts also recently weighed in on LQDA. Wedbush set a $58.00 target price on Liquidia in a research report on Friday, October 2nd. Bank of America lifted their price target on Liquidia from $79.00 to $92.00 and gave the company a “neutral” rating in a report on Thursday, August 13th. Wells Fargo & Company restated an “equal weight” rating and issued a $30.00 price target (down from $108.00) on shares of Liquidia in a report on Friday, October 2nd. Stephens set a $130.00 price objective on shares of Liquidia in a research note on Friday, July 24th. Finally, Citigroup reiterated a “neutral” rating on shares of Liquidia in a report on Thursday, October 1st. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $79.46.

Liquidia Stock Down 3.1%

LQDA stock opened at $26.81 on Wednesday. The company has a 50 day moving average price of $63.40 and a two-hundred day moving average price of $61.76. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.12 and a current ratio of 2.31. The stock has a market capitalization of $2.40 billion, a P/E ratio of 19.57 and a beta of 0.61. Liquidia has a one year low of $21.94 and a one year high of $93.61.

Liquidia (NASDAQ:LQDA) last issued its quarterly earnings results on Wednesday, August 12th. The company reported $0.74 earnings per share for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.02). Liquidia had a return on equity of 149.65% and a net margin of 30.74%. The business had revenue of $171.68 million for the quarter, compared to analysts’ expectations of $168.48 million. During the same period in the prior year, the company earned ($0.49) EPS. The company’s revenue for the quarter was up 1842.1% compared to the same quarter last year. As a group, sell-side analysts expect that Liquidia will post 2.05 EPS for the current year.

Insiders Place Their Bets

In related news, Director Stephen M. Bloch sold 235,477 shares of the stock in a transaction that occurred on Monday, October 5th. The shares were sold at an average price of $27.13, for a total transaction of $6,388,491.01. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Roger Jeffs sold 32,744 shares of the firm’s stock in a transaction that occurred on Monday, October 12th. The shares were sold at an average price of $28.48, for a total transaction of $932,549.12. Following the completion of the transaction, the chief executive officer owned 1,125,848 shares in the company, valued at $32,064,151.04. The trade was a 2.83% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last ninety days, insiders sold 745,194 shares of company stock worth $41,081,702. 25.60% of the stock is owned by insiders.

Institutional Investors Weigh In On Liquidia

Several institutional investors have recently bought and sold shares of LQDA. WINTON GROUP Ltd purchased a new stake in shares of Liquidia during the 2nd quarter valued at about $335,000. Arizona State Retirement System boosted its holdings in Liquidia by 5.4% in the 2nd quarter. Arizona State Retirement System now owns 17,627 shares of the company’s stock worth $1,405,000 after acquiring an additional 900 shares during the period. Nykredit A S purchased a new position in Liquidia in the 2nd quarter worth approximately $177,000. Corient Private Wealth LP acquired a new stake in Liquidia in the second quarter valued at approximately $758,000. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in Liquidia in the second quarter valued at approximately $1,236,000. 64.54% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Liquidia

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Liquidia reached a global settlement resolving all six pending lawsuits with United Therapeutics. The agreement allows uninterrupted commercialization of YUTREPIA for pulmonary arterial hypertension, removing years of patent, antitrust and trade-secret litigation uncertainty. Liquidia settlement announcement
• Positive Sentiment: Preliminary third-quarter YUTREPIA net sales reached $222.7 million, contributing to $396.1 million in cash and cash equivalents as of September 30. Management expects ongoing sales and existing cash to fund settlement obligations and planned clinical programs without new financing.
• Positive Sentiment: Liquidia plans to focus on expanding YUTREPIA in PAH while continuing development of the L606 clinical program and additional potential indications.
• Neutral Sentiment: CEO Roger Jeffs, CFO Michael Kaseta and several other insiders sold shares at $28.48 under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested equity awards. Because the sales were programmatic and insiders retained substantial holdings, they provide a limited standalone signal about management confidence. Liquidia insider transactions
• Negative Sentiment: The settlement requires Liquidia to pay United Therapeutics a net $380.7 million in installments during 2026 and 2027, including $175 million within 30 business days. The cash outflow could reduce financial flexibility and constrain investment, although management expects to rebuild cash through YUTREPIA sales.
• Negative Sentiment: Liquidia agreed not to appeal a patent-infringement ruling and is removing the PH-ILD indication from YUTREPIA’s label. It will also stop promoting Treprostinil Injection, narrowing potential revenue opportunities.
• Negative Sentiment: Insider activity remains heavily weighted toward sales, with 106 sales and one purchase reported over the past six months. Analysts have also recently lowered some price targets following the litigation setback, adding to investor caution.

Liquidia Company Profile

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with serious cardiopulmonary diseases and other rare conditions. The company uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition, with the goal of improving the delivery and performance of medicines.

Liquidia’s lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder inhaler designed for the treatment of pulmonary arterial hypertension (PAH).